J Studios
- Incyte (NASDAQ:INCY) reported early results from two studies on INCA033989, a new targeted antibody aimed at patients with blood disorders linked to mutant calreticulin.
- In these studies, 86% of high-risk patients with essential thrombocythemia who carried a CALR mutation and received 400